Serum Institute of India is developing ErepoXen product candidate, which is an enhanced polysialylated form of erythropoietin, a hormone produced by the kidneys to maintain red blood cell production and prevent anaemia caused by chronic kidney failure. ErepoXen uses Lipoxen's PolyXen® platform technology to attach polysialic acid, a polymer of sialic acid (a biodegradable sugar that is found naturally in the human body) to protein drugs.
The findings of phase I & phase II clinical trials suggest that the drug may beeffective when administered once monthly to patients with chronic kidney disease, thereby achieving maximal compliance and excellent outcome results. Serum Institute is working closely with Lipoxen U.K. to accelerate the commercialization of this candidate.
Sincerely Pharmaceutical Tech
Regards,
Client Success Team (CRM),
Please fill the all required fields....!!
Sincerely Packaging Labelling
